




## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : <b>C07D 401/14, A61K 31/495</b>	<b>A1</b>	(11) International Publication Number: <b>WO 98/38186</b> (43) International Publication Date: 3 September 1998 (03.09.98)
<p>(21) International Application Number: PCT/EP98/01275</p> <p>(22) International Filing Date: 24 February 1998 (24.02.98)</p> <p>(30) Priority Data: PCT/EP97/00995 27 February 1997 (27.02.97) WO (34) Countries for which the regional or international application was filed: CA et al. 9715783.8 25 July 1997 (25.07.97) GB</p> <p>(71) Applicant (for GB only): PFIZER LIMITED [GB/GB]; Ramsgate Road, Sandwich, Kent CT13 9NJ (GB).</p> <p>(71) Applicant (for all designated States except GB US): PFIZER INC. [US/US]; 235 East 42nd Street, New York, NY 10017 (US).</p> <p>(72) Inventors; and (75) Inventors/Applicants (for US only): STOBIE, Alan [GB/GB]; Pfizer Central Research, Ramsgate Road, Sandwich, Kent CT13 9NJ (GB). GAUTIER, Elisabeth, Colette, Louise [FR/GB]; Pfizer Central Research, Ramsgate Road, Sandwich, Kent CT13 9NJ (GB). WAITE, David, Charles [GB/GB]; Pfizer Central Research, Ramsgate Road, Sandwich, Kent CT13 9NJ (GB). CROOK, Robert, James</p>		<p>[GB/GB]; Pfizer Central Research, Ramsgate Road, Sandwich, Kent CT13 9NJ (GB).</p> <p>(74) Agents: RUDDOCK, Keith, Stephen et al.; Pfizer Limited, Ramsgate Road, Sandwich, Kent CT13 9NJ (GB).</p> <p>(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</p> <p>Published With international search report.</p>
<p>(54) Title: QUINOXALINEDIONES</p> <div style="text-align: center;">  <p>(I)</p> </div> <p>(57) Abstract</p> <p>The present invention provides a substantially pure compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, together with compositions containing, uses of, processes for the preparation of and intermediates used in the preparation of such compounds.</p>		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

### QUINOXALINEDIONES

This invention relates to 2,3(1H,4H)-quinoxalinedione derivatives which  
5 are selective antagonists of N-methyl-D-aspartate receptors. More particularly,  
this invention relates to 5-triazolyl-2,3(1H,4H)-quinoxalinedione derivatives and  
to the preparation of, compositions containing, and the uses of, such  
derivatives.

L-Glutamic acid is an excitatory amino acid neurotransmitter whose  
10 physiological role in the brain involves interaction with four receptors, three of  
which are named after the selective agonists NMDA (N-methyl-D-aspartate),  
AMPA (2-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) and kainate.  
The fourth receptor is termed the metabotropic receptor. In addition to a  
binding site for glutamic acid, the NMDA receptor possesses high affinity  
15 binding sites for dissociative anaesthetics (e.g. ketamine), polyamines (e.g.  
spermine), glycine and certain metal ions (e.g.  $Mg^{2+}$ ,  $Zn^{2+}$ ). Since the NMDA  
receptor has an absolute requirement to bind glycine for activation to occur,  
glycine antagonists can act as functional NMDA antagonists.

In the region of a cerebral infarct, anoxia, for example, causes  
20 abnormally high concentrations of glutamic acid to be released. This leads to  
an over-stimulation of NMDA receptors resulting in the degeneration and death  
of neurones. Thus, NMDA receptor antagonists, which have been shown to  
block the neurotoxic effects of glutamic acid *in vitro* and *in vivo*, may be useful  
in the treatment and/or prevention of any pathological condition in which NMDA  
25 receptor activation is thought to be important. Examples of such conditions  
include acute neurodegenerative disorders arising from events such as stroke,  
transient ischaemic attack, peri-operative ischaemia, global ischaemia  
(following cardiac arrest) and traumatic head injury to the brain or spinal cord.  
In addition, NMDA antagonists may be of use in treating certain chronic  
30 neurological disorders such as senile dementia, Parkinson's disease and  
Alzheimer's disease. They may also have utility in conditions in which

-2-

peripheral nerve function has been impaired such as retinal and macular degeneration.

Furthermore, NMDA antagonists have been shown to possess anti-convulsant and anxiolytic activity and may therefore be used to treat epilepsy and anxiety. NMDA antagonists may also attenuate the effects of alcohol withdrawal from physically dependent animals (K.A. Grant *et al.*, J. Pharm.Exp.Ther., **260**, 1017 (1992)) and thus NMDA antagonists may be of use in the treatment of alcohol addiction and pain. NMDA antagonists may also be useful in the treatment of hearing disorders (e.g. tinnitus), migraine and psychiatric disorders.

EP-A-0572852 describes pyrrol-1-yl-substituted 2,3(1H,4H)-quinoxalinedione derivatives useful for the treatment of neurodegenerative illnesses and neurotoxic disorders of the central nervous system.


EP-A-0556393 discloses, *inter alia*, imidazolyl- or triazolyl-substituted 2,3(1H,4H)-quinoxalinedione derivatives with glutamate receptor antagonising activity, particularly NMDA-glycine receptor and AMPA receptor antagonising activities. However, no 5-triazolyl-substituted compounds are specifically described therein.

International Patent Application Publication no. WO 97/32873 discloses 5-heteroaryl-2,3-(1H,4H)-quinoxalinedione derivatives with NMDA receptor antagonist activity. Example 114 of that Application allegedly describes the preparation of (-)-6,7-dichloro-5-[3-methoxymethyl-5-(1-oxidopyridin-3-yl)-4H-1,2,4-triazol-4-yl]-2,3(1H,4H)-quinoxalinedione. However, further analysis of the product of Example 114 shows the stated title compound to be bound to a stoichiometric quantity of silica (see Reference Example 1 herein). This silica complex has been shown to have different properties compared with, and to be distinct, analytically, from, the stated title compound. Example 114 of that Application therefore discloses the preparation of a different compound to the alleged title compound although the skilled person, realising that a silica complex had been obtained, could readily apply common knowledge to prepare the stated title compound therefrom.

-3-

The present compounds are potent antagonists of the NMDA (glycine site) receptor. In addition, they are highly selective antagonists for the NMDA (glycine site) receptor in comparison to the AMPA receptor to which they have  
5 little, if any, affinity.

The present invention provides a novel, substantially pure compound of the formula:



(I)

10

or a pharmaceutically acceptable salt or solvate thereof.

The expression "substantially pure" means the compound preferably is at least of 90% w/w purity, more preferably is at least of 95% w/w purity and most preferably is at least of 98% w/w purity. For the purpose of pharmaceutical  
15 applications, the compound would normally be manufactured to at least 99% w/w purity.

The pharmaceutically acceptable salts of the compounds of the formula (I) include the acid addition and the base salts thereof.

Suitable acid addition salts are formed from acids which form non-toxic  
20 salts and examples are the hydrochloride, hydrobromide, hydroiodide, sulphate, hydrogen sulphate, nitrate, phosphate, hydrogen phosphate, acetate, maleate, fumarate, lactate, tartrate, citrate, gluconate, succinate, benzoate, methanesulphonate, benzenesulphonate and p-toluenesulphonate salts.

-4-

Suitable base salts are formed from bases which form non-toxic salts and examples are the calcium, lithium, magnesium, potassium, sodium, zinc, ethanolamine, diethanolamine and triethanolamine salts.


- 5 For a review on suitable salts see Berge *et al*, J.Pharm.Sci., **66**, 1-19 (1977).

Suitable solvates include hydrates.

- The compounds of the formula (I) are single stereoisomers known as atropisomers. Atropisomers are isomers that can be separated only because  
10 rotation about single bonds is prevented or greatly slowed (see "Advanced Organic Chemistry", Third Edition, Jerry March, John Wiley and Sons (1985)). They may be prepared conventionally from a corresponding optically pure intermediate or by resolution of a racemic mixture containing the opposite stereoisomer. This can be achieved by H.P.L.C. of the corresponding  
15 racemate using a suitable chiral support or by fractional crystallisation of the diastereoisomeric salts formed by reaction of the corresponding racemate with a suitable optically active acid or base.

- The compounds of the formula (I) can be prepared by the following  
20 methods.


- 1) The compounds of the formula (I) can be prepared by acidic or basic hydrolysis of a compound of the formula:



25

wherein R is group of the formula:

-5-



and R<sup>1</sup> and R<sup>2</sup>, either when taken alone or together, represent a group or groups that can be hydrolytically cleaved under acidic or basic conditions to provide a quinoxalinedione of the formula (I). Such group or groups are conventional and suitable examples will be well-known to the skilled person. Where R is a group of the formula (III), the reaction is followed by separation of the atropisomer of the formula (I) using conventional conditions.

Preferably R<sup>1</sup> and R<sup>2</sup> are either each independently selected from C<sub>1</sub>-C<sub>4</sub> alkyl (preferably methyl or ethyl) and benzyl, optionally ring-substituted by from 1 to 3 substituents each independently selected from C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, halo, nitro and trifluoromethyl, or, when taken together, represent C<sub>1</sub>-C<sub>6</sub> alkylene, CH(phenyl), CH(4-methoxyphenyl) or CH(3,4-dimethoxyphenyl).

Preferably, the reaction is carried out by acidic hydrolysis of a compound of the formula (II).


In a typical procedure, a compound of the formula (II) is treated with an aqueous solution of a suitable acid, e.g. a mineral acid such as hydrochloric acid, optionally in the presence of a suitable organic co-solvent, e.g. 1,4-dioxane. The reaction is usually carried out by heating the mixture at up to the reflux temperature of the solvent(s).

The intermediates of the formula (II) can be prepared by conventional methods, for example,

-6-


a) by the route shown in Scheme I:

Scheme I



wherein R,  $\text{R}^1$  and  $\text{R}^2$  are as previously defined for a compound of the formula (II).

In a typical procedure, a 5-aminoquinoxaline of the formula (V) is reacted with a compound of the formula:



wherein  $\text{X}^1$  is a suitable leaving group, e.g. chloro or bromo, in a suitable solvent, e.g. toluene or dichloromethane, and optionally in the presence of a suitable acid acceptor, e.g. pyridine, to provide an amide of the formula (VI).


An amide of the formula (VI) can be converted to a thioamide of the formula (VII) by treatment with 2,4-bis(4-methoxyphenyl)-1,3-dithia-2,4-diphosphetane-2,4-disulphide (Lawesson's reagent) in a suitable solvent, e.g. toluene or tetrahydrofuran.



-7-

A thioamide of the formula (VII) can be converted to a compound of the formula (II) by treatment with a compound of the formula:

5




in the presence of mercury (II) oxide, optionally a desiccant, e.g. 4A molecular sieves, and a suitable solvent, e.g. n-butanol.

10


A compound of the formula (II) where R is a group of the formula (III) may be resolved to provide a compound of the formula (II) where R is a group of the formula (IV) using conventional techniques, e.g. chiral H.P.L.C.; or

15 b) by using a similar method to that shown in Scheme I to prepare the corresponding pyridine compound of the formula:



20

wherein R<sup>3</sup> is a group of the formula:




-8-

and  $R^1$  and  $R^2$  are as previously defined for a compound of the formula (II), followed by N-oxidation thereof.


The N-oxidation can be performed using 3-chloroperoxybenzoic acid in a suitable solvent, e.g. aqueous methanol or acetone. Other suitable N-oxidation conditions include using hydrogen peroxide in acetic acid, dimethyldioxirane in acetone, monoperphthalic acid in acetic acid/methanol, OXONE (trade mark, potassium peroxymonosulphate) in a suitable solvent such as water, acetone or dichloromethane, and sodium perborate in acetic acid.

Again, a compound of the formula (II) where R is a group of the formula (III) may be resolved to provide a compound of the formula (II) where R is a group of the formula (IV) as described in method (a) above.

- 2) The compounds of the formula (I) can also be prepared by N-oxidation of a compound of the formula:



where  $R^3$  is a group of the formula:



The N-oxidation can be carried out using a suitable oxidising agent, e.g. 3-chloroperoxybenzoic acid, and a suitable solvent, e.g. methanol or

-9-

acetone. Other suitable N-oxidation conditions include using hydrogen peroxide in acetic acid, dimethyldioxirane in acetone, monoperphthalic acid in acetic acid/methanol, OXONE (trade mark, potassium  
5 peroxymonosulphate) in a suitable solvent such as water, acetone or dichloromethane, and sodium perborate in acetic acid.

Where  $R^3$  is a group of the formula (IX), the reaction is followed by separation of the atropisomer of the formula (I) using conventional  
10 conditions.

The compounds of the formula (XI) may be prepared by acidic or basic hydrolysis of the compounds of the formula (VIII) using the conditions described in Method (1).  
15

3) A compound of the formula (I) can be prepared from its corresponding silica complex by treating a solution of the complex in a suitable solvent, e.g. methanol, with a suitable acid, e.g. a mineral acid (e.g. hydrochloric acid) or acetic acid. This acid treatment degrades the silica complex and  
20 liberates a compound of the formula (I).

During the preparation of a compound of the formula (I), the compound must not be treated with silica (e.g. during chromatography) otherwise it will become bound with a stoichiometric quantity thereof to form a different compound, i.e. a silica complex of the required  
25 compound.

Accordingly, a compound of the formula (I) is preferably purified by reverse phase gel chromatography.

-10-

All of the above reactions and the preparations of novel starting materials used in the preceding methods are conventional and appropriate reagents and reaction conditions for their performance or preparation as well as  
5 procedures for isolating the desired products will be well known to those skilled in the art with reference to literature precedents and the Examples and Preparations hereto.

A pharmaceutically acceptable acid addition or base salt of a compound of the formula (I) may be readily prepared by mixing together solutions of a  
10 compound of the formula (I) and the desired acid or base, as appropriate. The salt may precipitate from solution and be collected by filtration or may be recovered by evaporation of the solvent.

The binding affinity of compound of the formula (I) for the glycine site of the NMDA receptor may be measured by testing its ability to displace a  
15 selective glycine site radioligand from rat brain membranes as described in Brit. J. Pharm., **104**, 74 (1991). In a variation of this method, thoroughly washed membrane protein is incubated with [<sup>3</sup>H]-L-689,560 (Mol. Pharmacol., **41**, 923 (1992)) for 90 minutes using tris-acetate buffer (pH 7.4). Displacement of the radioligand, using a range of test compound concentrations, is used to derive  
20 IC<sub>50</sub> (50% inhibitory concentration) values.

Functional in vitro glycine antagonism is demonstrated by the ability of the compounds to inhibit the depolarisations in rat cortical slices induced by NMDA by a similar method to that described in J. Med. Chem., **33**, 789 (1990) and Brit. J. Pharm., **84**, 381 (1985). In a variation of the procedure, the  
25 response to a standard concentration of NMDA is measured in the presence of a range of test compound concentrations and the results obtained are used to derive EC<sub>50</sub> (50% effective concentration) values.

The binding affinity of the compounds of the invention for the AMPA receptor may be measured by testing their ability to displace the radioligand  
30 [<sup>3</sup>H]-AMPA from rat brain membranes. Membrane homogenate is incubated

-11-

with radioligand (10 nM) in the presence or absence of test compounds at various concentrations at 4°C for 45 minutes. Free and bound radiolabel are separated by rapid filtration and radioactivity is measured by liquid scintillation  
5 counting.

The compounds of the formula (I) can be administered to a subject to be treated alone, but will generally be administered in admixture with a pharmaceutically acceptable diluent or carrier selected with regard to the intended route of administration and standard pharmaceutical practice. For  
10 example, they can be administered orally, including sublingually, in the form of tablets containing such excipients as starch or lactose, or in capsules or ovules either alone or in admixture with excipients, or in the form of elixirs, solutions or suspensions containing flavouring or colouring agents. They can be injected parenterally, for example, intravenously, intramuscularly or subcutaneously.  
15 For parenteral administration, they are best used in the form of a sterile aqueous solution which may contain other substances, for example, enough salts or glucose to make the solution isotonic with blood.

The compounds have potential for absorption through the gastrointestinal tract and thus administration by slow release formulations is  
20 also possible.

In general, a therapeutically effective daily oral dose of the compounds of formula (I) is likely to range from 0.1 to 100 mg/kg body weight of the subject to be treated, preferably 1 to 20 mg/kg, and an intravenous or subcutaneous daily dose is likely to range from 0.01-20mg/kg body weight of subject to be  
25 treated, preferably 0.1-20 mg/kg. The compounds of the formula (I) may also be administered by intravenous infusion at a dose which is likely to range from 0.01-10 mg/kg/hr.

Tablets or capsules of the compounds may be administered singly or two or more at a time, as appropriate.

-12-

The physician will determine the actual dosage which will be most suitable for an individual patient and it will vary with the age, weight and response of the particular patient. The above dosages are exemplary of the average case. There can, of course, be individual instances where higher or lower dosage ranges are merited and such are within the scope of this invention.

Alternatively, the compounds of the formula (I) can be administered by inhalation or in the form of a suppository or pessary, or they may be applied topically in the form of a lotion, solution, cream, ointment or dusting powder. An alternative means of transdermal administration is by use of a skin patch. For example, they can be incorporated into a cream consisting of an aqueous emulsion of polyethylene glycols or liquid paraffin. They can also be incorporated, at a concentration of between 1 and 10% by weight, into an ointment consisting of a white wax or white soft paraffin base together with such stabilisers and preservatives as may be required.

It is to be appreciated that reference to treatment includes prophylaxis as well as the alleviation of established symptoms of the disease.

Thus the invention further provides:-

- i) a pharmaceutical composition comprising a compound of the formula (I), or a pharmaceutically acceptable salt or solvate thereof, together with a pharmaceutically acceptable diluent or carrier;
- ii) a compound of the formula (I), or a pharmaceutically acceptable salt, solvate or composition thereof, for use as a medicament;
- iii) the use of a compound of the formula (I), or of a pharmaceutically acceptable salt, solvate or composition thereof, for the manufacture of a medicament for the treatment of a disease by producing an antagonist effect at a NMDA receptor;
- iv) use as in (iii) where the disease is an acute neurodegenerative or a chronic neurological disorder;

-13-

- v) a method of treatment of a mammal to treat a disease by producing an antagonist effect at a NMDA receptor, which comprises treating said mammal with an effective amount of a compound of the formula (I) or  
5 with a pharmaceutically acceptable salt, solvate or composition thereof;
- vi) a method as in (v) where the disease is an acute neurodegenerative or a chronic neurological disorder;
- vii) a compound of the formula (II) where R is a group of the formula (III) or (IV); and
- 10 viii) a compound of the formula (VIII) where  $R^3$  is a group of the formula (X).

-14-

The following Examples illustrate the preparation of the compounds of the formula (I) and a composition thereof.

- 5           Melting points were determined using a Buchi apparatus in glass capillary tubes and are uncorrected. Low Resolution Mass Spectroscopic (LRMS) data were recorded on a Fisons Trio 1000 Mass Spectrometer (thermospray using ammonium acetate in aqueous methanol as the carrier or atmospheric pressure chemical ionisation (APCI) using 97.5:2.5, by volume, methanol:acetic acid and gaseous nitrogen as the carrier). NMR data were  
10 recorded on a Varian Unity 300 or a Varian Inova 400 NMR instrument (300 and 400 MHz, respectively) and were consistent with the assigned structures. Proton NMR shifts are quoted in parts per million downfield from tetramethylsilane. The purity of the compounds was carefully assessed using  
15 analytical TLC and proton NMR and the latter technique was used to calculate the amount of solvent present in solvated samples. The term "residue" used in the microanalysis data indicates the residual material remaining following combustion, i.e. the non-flammable material.




-15-

EXAMPLE 1

(-)-6,7-Dichloro-5-[3-methoxymethyl-5-(1-oxidopyridin-3-yl)-4H-1,2,4-triazol-4-yl]-2,3(1H,4H)-quinoxalinedione hydrate

5



Concentrated hydrochloric acid (1ml) was added to a stirred solution of (-)-6,7-dichloro-5-[3-methoxymethyl-5-(1-oxidopyridin-3-yl)-4H-1,2,4-triazol-4-yl]-2,3(1H,4H)-quinoxalinedione, silica complex (See Reference Example 1) (2.3g, 4.64mmol) in methanol (40ml) and the mixture stirred for 2 hours. The solid precipitate was collected by filtration to afford the title compound as a white solid (1.4g, 65%). mp 264-265°C.

Found: C, 44.34; H, 3.21; N, 18.14; residue, 0.00.

15  $C_{17}H_{12}Cl_2N_6O_4 \cdot 1.5 H_2O$  requires C, 44.17; H, 3.21; N, 18.18; residue 0.00%.

$^1H$ -NMR (300 MHz,  $d_6$ -DMSO):  $\delta$  = 3.12 (3H, s), 4.36 (2H, m), 7.18 (1H, d,  $J$  = 9.5Hz), 7.36 (1H, dd,  $J_1 = J_2 = 9.5$ Hz), 7.42 (1H, s), 8.24 (1H, d,  $J$  = 9.5Hz), 8.30 (1H, s), 12.22 (1H, s), 12.24 (1H, s).

20


m/z (thermospray): 435 ( $MH^+$ ).

$[\alpha]_D^{25} -235^\circ$  ( $c=0.1$ , water)

-16-

## EXAMPLE 2

(-)-6,7-Dichloro-5-[3-methoxymethyl-5-(1-oxidopyridin-3-yl)-4H-1,2,4-triazol-4-yl]-2,3(1H,4H)-quinoxalinedione hydrate



5

A solution of 3-chloroperoxybenzoic acid (50-55% w/w in water containing 3-chlorobenzoic acid impurity, 16.1g, 47mmol) in methanol (200ml) was added to a solution of (-)-6,7-dichloro-5-[3-methoxymethyl-5-(3-pyridyl)-4H-1,2,4-triazol-4-yl]-2,3(1H,4H)-quinoxalinedione (see Preparation 1) (13.8g, 31mmol) in methanol (400ml) at room temperature. The reaction mixture was stirred at room temperature for 3.5 days. The reaction mixture was pre-absorbed on reverse phase gel (MCI Gel CHP20P [trade mark], 75-100 $\mu$ ) and purified by chromatography on reverse phase gel (MCI Gel CHP20P [trade mark], 75-100 $\mu$ ) by gradient elution using water:methanol (3:1 changing to 2:1, by volume) as the eluent to give, after combination and concentration of the appropriate fractions, a light yellow solid which was recrystallised from methanol to give the title compound (7.6g, 54%) as a colourless solid. mp 265-267°C.

Found: C, 45.01; H, 3.08; N, 18.65. C<sub>17</sub>H<sub>12</sub>Cl<sub>2</sub>N<sub>6</sub>O<sub>4</sub>.H<sub>2</sub>O requires C, 45.05; H, 3.11; N, 18.54%.

20

-17-

<sup>1</sup>H-NMR (300 MHz, d<sub>6</sub>-DMSO): Identical spectrum to that obtained for the compound of Example 1.

5 m/z (thermospray): 435 (MH<sup>+</sup>)

[α]<sub>D</sub><sup>25</sup> -224° (c=0.1, water)

10

### EXAMPLE 3

(-)-6,7-Dichloro-5-[3-methoxymethyl-5-(1-oxidopyridin-3-yl)-4H-1,2,4-triazol-4-yl]-2,3(1H,4H)-quinoxalinedione

15 (-)-6,7-Dichloro-5-[3-methoxymethyl-5-(3-pyridyl)-4H-1,2,4-triazol-4-yl]-2,3(1H,4H)-quinoxalinedione (see Preparation 1) (412.2g, 0.98 mol) and OXONE (trade mark) (1.44 kg, 2.3 mol) were slurried in water (4.13 L) and the mixture stirred at ambient temperature for 60 hours. Saturated aqueous sodium thiosulphate solution (2.2 L) was added and the slurry stirred for 1 hour  
20 before being filtered under reduced pressure. The filter cake was slurried at ambient temperature for 4 hours in 1:1, by volume, isopropyl alcohol: dichloromethane (111 L) and the solid collected by filtration. The filtrate was evaporated under reduced pressure to give the title compound as a colourless solid (366 g).

25

### EXAMPLE 4

(-)-6,7-Dichloro-5-[3-methoxymethyl-5-(1-oxidopyridin-3-yl)-4H-1,2,4-triazol-4-yl]-2,3(1H,4H)-quinoxalinedione, sodium salt, hydrate

30 Sodium hydroxide (9.72ml of a 1 molar aqueous solution, 9.72mmol) was added to a stirred suspension of (-)-6,7-dichloro-5-[3-methoxymethyl-5-(1-oxidopyridin-3-yl)-4H-1,2,4-triazol-4-yl]-2,3(1H,4H)-quinoxalinedione hydrate (see Example 2) (4.406g, 9.72mmol) in water (60ml) and the mixture stirred for

-18-

5 minutes. The resulting solution was filtered and the filtrate freeze-dried to give the title compound (4.5g, 98%) as a pale yellow solid. mp 303°C (decomp.).

5

Found: C, 41.40; H, 3.05; N, 16.99.  $C_{17}H_{11}Cl_2N_6NaO_4 \cdot 2H_2O$  requires C, 41.40; H, 3.07; N, 17.04%.

$^1H$ -NMR (400 MHz,  $d_6$ -DMSO):  $\delta$  = 3.08 (3H, s), 4.24 (2H, m), 7.22 (2H, m),  
10 7.38 (1H, dd,  $J_1 = J_2 = 9.5$ Hz), 8.02 (1H, s), 8.20 (1H, m), 11.66 (1H, s).

$[\alpha]_D^{25} -277^\circ$  (c=0.1, water)

#### EXAMPLE 5

15 Intravenous formulation of (-)-6,7-Dichloro-5-[3-methoxymethyl-5-(1-oxidopyridin-3-yl)-4H-1,2,4-triazol-4-yl]-2,3(1H,4H)-quinoxalinedione, sodium salt, hydrate

A formulation suitable for administering a 20mg/ml dose of the active  
20 component by intravenous injection was prepared using (-)-6,7-dichloro-5-[3-methoxymethyl-5-(1-oxidopyridin-3-yl)-4H-1,2,4-triazol-4-yl]-2,3(1H,4H)-quinoxalinedione, sodium salt,  $2H_2O$  (see Example 4) (22.7mg per unit dose), sodium chloride (9.0mg per unit dose) and water for injections (to 1.0ml).


25 To prepare the formulation, sodium chloride is dissolved in 75% of the total volume of water in a suitable vessel with mixing. (-)-6,7-Dichloro-5-[3-methoxymethyl-5-(1-oxidopyridin-3-yl)-4H-1,2,4-triazol-4-yl]-2,3(1H,4H)-quinoxalinedione, sodium salt,  $2H_2O$  is then added and dissolved by mixing. The solution is then made up to volume with water and filtered through a  
30 clarifying 0.2 micron filter. The filtrate is filled into sterile 10ml glass ampoules under aseptic conditions using a terminal clarifying filter and the ampoules sealed.

-19-

Part (i) of the following Reference Example 1 is a repeat preparation of the compound of Example 114 of International Patent Application Publication no. WO 97/32873. In Part (ii), the product obtained was recrystallised from aqueous acetone.

### REFERENCE EXAMPLE 1

(-)-6,7-Dichloro-5-[3-methoxymethyl-5-(1-oxidopyridin-3-yl)-4H-1,2,4-triazol-4-yl]-2,3(1H,4H)-quinoxalinedione, silica complex



10

(i) A solution of 3-chloroperoxybenzoic acid (0.85g, 4.93 mmol) in acetone (20ml) was added in one portion to a suspension of (-)-6,7-dichloro-5-[3-methoxymethyl-5-(3-pyridyl)-4H-1,2,4-triazol-4-yl]-2,3(1H,4H)-quinoxalinedione (see Preparation 1) (1.0g, 2.24 mmol) in acetone (40ml) which caused all the solid to dissolve. The reaction was stirred at room temperature for 40 minutes after which time a white solid began to form. The reaction mixture was allowed to stir at room temperature for 3 days. The white solid was collected by filtration (this solid contained less than 90% w/w of the N-oxide product)<sup>1</sup> and subjected to flash chromatography on silica gel using dichloromethane:methanol:glacial acetic acid (90:10:1, by volume) as the eluant to give, after combination and concentration of the appropriate fractions, the title compound as a white solid, (0.16g). m.p. >310 °C.

15

20

25

<sup>1</sup>H-NMR (300 MHz, d<sub>6</sub>-DMSO): δ = 1.90 (s, acetic acid 0.3 eq), 3.10 (3H, s), 4.32 (2H, m), 7.22 (1H, m), 7.40 (2H, m), 8.10 (1H, m), 8.22 (1H, m).

-20-

m/z (thermospray): 435.

5  $[\alpha]_D^{25} -235^\circ$  (c=0.1, ethanol)\*

(\*It should be noted that a clerical error occurred when stating the  $[\alpha]_D^{25}$  value in Example 114 of International Patent Application Publication no. WO 97/32873. The stated "c = 1.0" value is incorrect and this should  
10 have read "c = 0.1").

(ii) Recrystallisation of this solid from aqueous acetone gave the title compound as a white solid. mp >310°C.

15 Found: C, 41.2; H, 3.1; N, 17.0; residue, 8.25.

$C_{17}H_{12}Cl_2N_6O_4 \cdot 0.5 H_2SiO_3 \cdot 1.2 H_2O$  requires: C, 41.18; H, 3.13; N, 16.95; residue 7.87%.

$^1H$ -NMR (300 MHz,  $d_6$ -DMSO):  $\delta$  = 3.05 (3H, s), 4.37 (2H, m), 7.16 (1H, d, J = 9.5Hz), 7.32 (1H, s), 7.32 (1H, m), 7.98 (1H, s), 8.18 (1H, d, J =  
20 9.5Hz).

$[\alpha]_D^{25} -199^\circ$  (c=0.1, methanol)

25

#### Footnote

1. The method of Reference Example 1 (i) was repeated exactly and the precipitated white solid was collected by filtration (0.507 g).

This was found to contain 57.7% w/w (-)-6,7-dichloro-5-[3-methoxymethyl-5-(1-oxidopyridin-3-yl)-4H-1,2,4-triazol-4-yl]-2,3(1H,4H)-quinoxalinedione when analysed by high pressure liquid chromatography (HPLC) using a 15 cm x 0.46 cm i.d. Magellen (trade mark) C18 column and a gradient elution employing the following combinations of solvent A (acetonitrile)  
30

-21-

and solvent B (8.3 mM phosphate buffer adjusted to pH3.7 using phosphoric acid):

5

Time (min.)	% (by volume) A	% (by volume) B	Duration (min.)
	2	98	(Initial)
0	98	2	30
35	2	98	1
45			(Finish)

at a flow rate of 1 ml/min. and at ambient temperature.

The components of the eluted mixture were detected at a wavelength of 220 nm and samples of the compounds of Examples 4 and Preparation 1 and  
10 of 3-chloroperoxybenzoic acid were used as reference standards.


-22-

The following Preparations describe the manufacture of certain intermediates used in the preceding Examples and Reference Example.

5

### PREPARATION 1

(±)-, (-)- and (+)-6,7-Dichloro-5-[3-methoxymethyl-5-(3-pyridyl)-4H-1,2,4-triazol-4-yl]-2,3(1H,4H)-quinoxalinedione



10

- (a) Methoxyacetylchloride (27.3ml, 32.4g, 0.30mol) was added to a stirred mixture of 5-amino-6,7-dichloro-2,3-dimethoxyquinoxaline (Preparation 2) (73.8g, 0.27mol) and pyridine (26.4ml, 25.8g, 0.33mol) in dichloromethane (1.2 litres) at room temperature under nitrogen. After 18 hours stirring at room temperature, the mixture was washed with 2M aqueous hydrochloric acid solution followed by brine, then dried (MgSO<sub>4</sub>) and concentrated under reduced pressure. The residue was triturated

15



-23-

with methanol and filtered to give 6,7-dichloro-2,3-dimethoxy-5-methoxyacetamidoquinoxaline (82.0g, 88%) as an off-white solid. mp 171-173°C.

5

Found: C, 44.97; H, 3.75; N, 12.03.  $C_{13}H_{13}Cl_2N_3O_4$  requires C, 45.11; H, 3.79; N, 12.14%.

(b) 2,4-Bis(4-methoxyphenyl)-1,3-dithia-2,4-diphosphetane-2,4-disulphide (Lawesson's reagent) (19.5g, 48.2mmol) was added to a solution of 6,7-dichloro-2,3-dimethoxy-5-methoxyacetamidoquinoxaline (27g, 78mmol) in tetrahydrofuran (480ml) and the mixture was stirred for 18 hours at room temperature, then evaporated under reduced pressure. The residue was purified by flash chromatography on silica gel by gradient elution using hexane:dichloromethane (1:1 changing to 1:4, by volume) as the eluent to give 6,7-dichloro-2,3-dimethoxy-5-methoxythioacetamidoquinoxaline (29.1g, >100%) as a white solid, mp 198-200°C, containing a minor impurity.

Found: C, 43.06; H, 3.65; N, 11.59.  $C_{13}H_{13}Cl_2N_3O_3S$  requires C, 43.11; H, 3.62; N, 11.60%.

(c) A mixture of 6,7-dichloro-2,3-dimethoxy-5-methoxythioacetamidoquinoxaline (25.3g, 69.9mmol), nicotinic acid hydrazide (19.3g, 140.8mmol), mercury(II) oxide (15.1g, 69.7mmol) and 1,4-dioxane (600ml) was heated under reflux for 18 hours. After cooling, the mixture was filtered through ARBOCEL (trade mark) filter aid and the residue washed with dichloromethane. The filtrate was concentrated under

-24-

reduced pressure to afford a light brown solid which was partitioned between ethyl acetate and 2M aqueous hydrochloric acid solution. The layers were separated and the aqueous layer was extracted with dichloromethane (2x500ml, 4x100ml). The combined dichloromethane extracts were dried ( $\text{MgSO}_4$ ) and concentrated under reduced pressure. The residue was crystallised from ethyl acetate/methanol to give ( $\pm$ )-6,7-dichloro-2,3-dimethoxy-5-[3-methoxymethyl-5-(3-pyridyl)-4H-1,2,4-triazol-4-yl]]quinoxaline (11.6g, 37%) as a pale yellow solid. mp 189-191°C.

Found: C, 50.10; H, 3.57; N, 18.53.  $\text{C}_{19}\text{H}_{16}\text{Cl}_2\text{N}_6\text{O}_3 \cdot 0.5\text{H}_2\text{O}$  requires: C, 50.01; H, 3.76; N, 18.42%.

(d) A mixture of ( $\pm$ )-6,7-dichloro-2,3-dimethoxy-5-[3-methoxymethyl-5-(3-pyridyl)-4H-1,2,4-triazol-4-yl]]quinoxaline (3.0g, 6.7mmol), 2M aqueous hydrochloric acid solution (10ml) and 1,4-dioxane (50ml) was heated under reflux for 9 hours, cooled, and concentrated under reduced pressure. The residue was dissolved in 1M aqueous sodium hydroxide solution and acidified to pH 4.5 with concentrated hydrochloric acid to afford a thick white precipitate. This was collected by filtration and washed with water to give ( $\pm$ )-6,7-dichloro-5-[3-methoxymethyl-5-(3-pyridyl)-4H-1,2,4-triazol-4-yl]-2,3(1H,4H)-quinoxalinedione (2.0g, 68%) as an off-white solid. mp 230-232°C.

Found: C, 46.23; H, 2.93; N, 19.00.  $\text{C}_{17}\text{H}_{12}\text{Cl}_2\text{N}_6\text{O}_3 \cdot 1.25\text{H}_2\text{O}$  requires: C, 46.22; H, 3.31; N, 19.02%.

(e) (i) (-)-N-Methylephedrine (0.88g, 4.9mmol) and then methanol (66ml) were added to a stirred suspension of ( $\pm$ )-6,7-dichloro-5-[3-methoxymethyl-5-(3-pyridyl)-4H-1,2,4-triazol-4-yl]-2,3(1H,4H)-quinoxalinedione (1.9g,

-25-

4.3mmol) in ethyl acetate (400ml) at room temperature. The mixture was heated to its boiling point. The mixture was filtered, the filtrate concentrated to three quarters of its volume and then cooled to room temperature. The solid obtained was collected by filtration and washed with ethyl acetate. The solid was crystallised from ethyl acetate/methanol to give a single diastereoisomer of the quinoxalinedione starting material as the (-)-N-methylephedrine salt (1.28g, 43%). mp 162-164°C.

Found: C, 55.74; H, 5.38; N, 14.38.  $C_{28}H_{29}Cl_2N_7O_4 \cdot CH_3CO_2C_2H_5$  requires: C, 55.98; H, 5.43; N, 14.28%.

$[\alpha]_D^{25} -135^\circ$  (c=0.1, ethanol).

(ii) A suspension of the (-)-N-methylephedrine salt (1.2g, 1.7mmol) from part (e)(i) in water (13ml) at room temperature was acidified to pH 5 with concentrated hydrochloric acid and the suspension was stirred for 1 hour. The solid obtained was collected by filtration, washed with water and crystallised from water/ethanol to give (-)-6,7-dichloro-5-[3-methoxymethyl-5-(3-pyridyl)-4H-1,2,4-triazol-4-yl]-2,3(1H,4H)-quinoxalinedione (0.48g, 62%) as a white solid. mp 220-222°C.

Found: C, 45.49; H, 3.21; N, 18.72.  $C_{17}H_{12}Cl_2N_6O_3 \cdot 1.5H_2O$  requires C, 45.76; H, 3.39; N, 18.83%.

$[\alpha]_D^{25} -214^\circ$  (c=0.1, ethanol).

(iii) The combined filtrates from part (e)(i) were concentrated to dryness, the residue dissolved in water (20ml), acidified to pH 3 with concentrated

-26-

hydrochloric acid and the solid obtained was collected by filtration, washed with water and dried. (+)-N-Methylephedrine (0.37g, 2.06mmol) and then methanol (28ml) were added to a stirred suspension of this solid (0.80g, 1.87mmol) in ethyl acetate (170ml) at room temperature and the mixture was heated to its boiling point. The mixture was filtered, concentrated to three quarters of its volume and then cooled to room temperature. The solid obtained was collected by filtration and washed with ethyl acetate. The solid was crystallised from ethyl acetate/methanol to give a single diastereoisomer of the quinoxalinedione starting material as the (+)-N-methylephedrine salt (0.93g, 32%) as a white solid. mp 165-167°C.

Found: C, 55.88; H, 5.40; N, 14.31.  $C_{28}H_{29}Cl_2N_7O_4 \cdot 0.8 CH_3CO_2C_2H_5$  requires: C, 56.01; H, 5.33; N, 14.66%.


$[\alpha]_D^{25} +127^\circ$  (c=0.1, ethanol).

(iv) A suspension of the (+)-N-methylephedrine salt (0.90g, 1.35mmol) from part (e) (iii) in water (10ml) at room temperature was acidified to pH 5 with concentrated hydrochloric acid and the suspension was stirred for 1 hour. The solid was collected by filtration and washed with water to give (+)-6,7-dichloro-5-[3-methoxymethyl-5-(3-pyridyl)-4H-1,2,4-triazol-4-yl]-2,3(1H,4H)-quinoxalinedione (0.41g, 69%) as a white solid. mp 222-224°C.

Found: C, 46.44; H, 3.18; N, 19.01.  $C_{17}H_{12}Cl_2N_6O_3 \cdot 1.25H_2O$  requires C, 46.22; H, 3.31; N, 19.02%.

$[\alpha]_D^{25} +212^\circ$  (c=0.1, ethanol).

-27-

PREPARATION 25-Amino-6,7-dichloro-2,3-dimethoxyquinoxaline

5

- (a) A mixture of 6,7-dichloro-5-nitro-2,3(1H,4H)-quinoxalinedione (Example 1 of WO-A-94/00124, 84 g, 0.34 mol), thionyl chloride (840ml) and dimethylformamide (0.5ml) was heated under reflux for 3 hours, cooled and concentrated under reduced pressure. Ethyl acetate (300ml) was added and removed by evaporation under reduced pressure and this procedure was then repeated with petroleum ether (bp 100-120°C). The solid residue was recrystallised from petroleum ether (bp 100-120°C) to give 2,3,6,7-tetrachloro-5-nitroquinoxaline (78g, 73%) as a light yellow solid.

15

<sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>): δ = 8.6 (1H, s).

- (b) Tin(II) chloride dihydrate (346.3g, 1.54mol) was added to a solution of 2,3,6,7-tetrachloro-5-nitroquinoxaline (96.2g, 0.31mol) in ethyl acetate (1.8 litres). The mixture was heated under reflux for 4 hours, cooled and poured cautiously into an excess of aqueous saturated sodium bicarbonate solution. The mixture was filtered through CELITE (trade

20

-28-

mark) filter aid washing well with ethyl acetate. The filter cake was macerated with further ethyl acetate and the solid material filtered off. The combined ethyl acetate phases were dried ( $\text{MgSO}_4$ ) and concentrated under reduced pressure to give 5-amino-2,3,6,7-tetrachloroquinoxaline (73.4g, 84%) as a yellow solid.

$^1\text{H-NMR}$  (300 MHz,  $\text{CDCl}_3$ ):  $\delta$  = 5.45 (2H, br, s), 7.47 (1H, s).

m/z (thermospray): 385 ( $\text{MH}^+$ ).

(In an alternative preparation, this reduction step was performed using iron filings in aqueous acetic acid).

- (c) A solution of sodium methoxide (25% w/w solution in methanol, 274ml, 1.28mol) was added to a suspension of 5-amino-2,3,6,7-tetrachloroquinoxaline (72.4g, 0.256mol) in dry methanol (1 litre) and the resulting mixture was heated under reflux for 30 minutes. The mixture was cooled, concentrated under reduced pressure, and the residue partitioned between water and ethyl acetate (total of 8 litres). The organic extracts were dried ( $\text{MgSO}_4$ ) and concentrated under reduced pressure. The crude product was triturated with methanol then dissolved in dichloromethane (2 litres) and filtered. The filtrate was concentrated under reduced pressure to give the title compound as a yellow solid (55.0g, 79%).

$^1\text{H-NMR}$  (300 MHz,  $\text{CDCl}_3$ ):  $\delta$  = 4.13 (3H, s), 4.14 (3H, s), 5.07 (2H, br s), 7.26 (1H, s).

m/z (thermospray): 274 ( $\text{MH}^+$ ).

(In an alternative preparation, toluene was used as a co-solvent with methanol).

-29-

Solubility data

5 The compounds of Examples 1 and 2 and Reference Example 1 were tested for their solubility in water and methanol at ambient temperature.

The results are shown in the Table below.

Reference	Solubility in water at pH 7.3 (mg/ml)	Solubility in methanol (mg/ml)
Example 1 and 2	>20 mg/ml	<1 mg/ml
Reference Example 1	<1 mg/ml	<u>ca.</u> 15 mg/ml

10

Lipophilicity data

The lipophilicities of the compounds of Example 2 and Reference Example 1 were tested by the octanol/water partition method.

Reference	log D
Example 2	-1.7
Reference Example 1	-0.6

-30-

Pharmacological data

The binding affinities for the glycine site of the NMDA receptor and the functional in vitro glycine antagonism of the compounds of Example 2 and

5 Reference Example 1 were measured by the methods described on page 10.

The results were as follows:

Binding affinity	
Example 2	IC <sub>50</sub> = 2.4 nm
Reference Example 1	IC <sub>50</sub> = 3.8 nm


Functional <u>in vitro</u> glycine antagonism	
Example 2	IC <sub>50</sub> = 140 nm
Reference Example 1	IC <sub>50</sub> = 190 nm



-31-

CLAIMS

1. A substantially pure compound of the formula:



(I)

5


or a pharmaceutically acceptable salt or solvate thereof.

2. A compound as claimed in claim 1 that is at least of 90% w/w purity.
- 10 3. A compound as claimed in claim 2 that is at least of 95% w/w purity.
4. A compound as claimed in claim 3 that is at least of 98% w/w purity.
5. A compound as claimed in any one of claims 1 to 4 wherein the
- 15 pharmaceutically acceptable salt is a sodium salt.
6. A pharmaceutical composition comprising a compound of the formula (I), or a pharmaceutically acceptable salt or solvate thereof, as claimed in any one of claims 1 to 5, together with a pharmaceutically acceptable diluent or carrier.
- 20 7. A compound of the formula (I), or a pharmaceutically acceptable salt, solvate or composition thereof, as claimed in any one of claims 1 to 5 and 6, respectively, for use as a medicament.
8. The use of a compound of the formula (I), or of a pharmaceutically acceptable salt, solvate or composition thereof, as claimed in any one of claims

-32-


1 to 5 and 6, respectively, for the manufacture of a medicament for the treatment of a disease by producing an antagonist effect at a NMDA receptor.

9. Use as claimed in claim 8 where the disease is an acute
- 5 neurodegenerative or a chronic neurological disorder;
10. A method of treatment of a mammal to treat a disease by producing an antagonist effect at a NMDA receptor, which comprises treating said mammal with an effective amount of a compound of the formula (I) or with a pharmaceutically acceptable salt, solvate or composition thereof, as claimed
- 10 in any one of claims 1 to 5 and 6, respectively.
11. A method as claimed in claim 10 where the disease is an acute neurodegenerative or a chronic neurological disorder.
12. A compound of the formula:



15

wherein R is group of the formula:




20

and R<sup>1</sup> and R<sup>2</sup>, either when taken alone or together, represent a group or groups that can be hydrolytically cleaved under acidic or basic conditions to provide the corresponding quinoxalinedione.

-33-


13. A compound of the formula (II) as claimed in claim 12 wherein  $R^1$  and  $R^2$  are either each independently selected from  $C_1$ - $C_4$  alkyl (preferably methyl or ethyl) and benzyl, optionally ring-substituted by from 1 to 3
- 5 substituents each independently selected from  $C_1$ - $C_4$  alkyl,  $C_1$ - $C_4$  alkoxy, halo, nitro and trifluoromethyl, or, when taken together, represent  $C_1$ - $C_6$  alkylene, CH(phenyl), CH(4-methoxyphenyl) or CH(3,4-dimethoxyphenyl).

14. A compound of the formula:



(VIII)


wherein  $R^3$  is a group of the formula:



(X)

- 15 and  $R^1$  and  $R^2$  are as defined in claim 12 or 13.


15. A process for the preparation of a compound of the formula (I), or a pharmaceutically acceptable salt or solvate thereof, as claimed in claim 1 comprising acidic or basic hydrolysis of a compound of the formula:




(II)

- 20 wherein R is group of the formula:


-34-



- 5            and  $R^1$  and  $R^2$ , either when taken alone or together, represent a group or groups that can be hydrolytically cleaved under acidic or basic conditions to provide the corresponding quinoxalinedione, said process being followed by:
- 10            (i)        when a compound of the formula (II) wherein R is a group of the formula (III) is used, separation of the atropisomer of the formula (I); and/or
- (ii)        , optionally, conversion of a compound of the formula (I) to a pharmaceutically acceptable salt or solvate thereof.
16.        A process for the preparation of a compound of the formula (I), or
- 15        a pharmaceutically acceptable salt or solvate thereof, as claimed in claim 1 comprising N-oxidation of a compound of the formula:



where  $R^3$  is a group of the formula:



20

-35-

followed by work-up of the reaction under silica-free conditions, said process being followed by:

5 (i) when a compound of the formula (XI) wherein R is a group of the formula (IX) is used, separation of the atropisomer of the formula (I); and/or

(ii) , optionally, conversion of a compound of the formula (I) to a pharmaceutically acceptable salt or solvate thereof.

10 17. A process as claimed in claim 16 wherein the N-oxidation is carried out using OXONE (trade mark) in a reaction-inert solvent.

18. A process as claimed in claim 17 wherein the reaction-inert solvent is water.

15 19. A process for the preparation of a compound of the formula (I), or a pharmaceutically acceptable salt or solvate thereof, as claimed in claim 1 comprising acidic treatment of a silica complex of a compound of the formula (I), said process being optionally followed by conversion of a compound of the formula (I) to a pharmaceutically acceptable salt or solvate thereof.

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 98/01275

**A. CLASSIFICATION OF SUBJECT MATTER**  
IPC 6 C07D401/14 A61K31/495

According to International Patent Classification(IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 0 556 393 A (YAMANOUCI) 25 August 1993  see page 13 - page 20 ----	1,5,7,8, 12-16
P,A	WO 97 32873 A (PFIZER) 12 September 1997 see page 81; claims -----	1-16



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

\* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

5 June 1998

Date of mailing of the international search report

16/06/1998

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Francois, J

# INTERNATIONAL SEARCH REPORT

Information on patent family members

In International Application No

PCT/EP 98/01275

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 556393 A	25-08-1993	AU 656154 B	27-01-1995
		AU 8766691 A	26-05-1992
		HU 64324 A	28-12-1993
		HU 9500644 A	28-11-1995
		WO 9207847 A	14-05-1992
		JP 2550456 B	06-11-1996
		RU 2095352 C	10-11-1997
		US 5283244 A	01-02-1994
WO 9732873 A	12-09-1997	AU 2023197 A	22-09-1997